Profound Medical Corp PRN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Emmy-Award Winning Television Host Montel Williams to Join Next ‘Let’s Huddle’ Webinar
-
Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
-
Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue
-
Profound Medical to Participate in Lake Street’s 10th Annual Best Ideas Growth Conference
-
Profound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as President
-
Profound’s Introduction of New Real-time Interventional MRI Software Paving the Way for Full ‘TULSA Days’
-
Profound Medical Announces Management Change
-
Profound Medical Launches ‘Let's Huddle’, a Global Community Supporting Men Throughout Their Prostate Care Journey
Trading Information
- Previous Close Price
- CA$8.08
- Day Range
- CA$7.76–8.05
- 52-Week Range
- CA$6.52–12.40
- Bid/Ask
- CA$7.70 / CA$9.38
- Shares Outstanding
- 36.54M
- Market Cap
- CA$284.65M
- Volume/Avg
- 18,855 / 15,228
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.85
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 162
- Website
- https://www.profoundmedical.com
Valuation
|
Metric
|
PRN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.02 |
Price/Sales | 9.85 |
Price/Cash Flow | — |
Price/Earnings
PRN
Financial Strength
|
Metric
|
PRN
|
|---|---|
Quick Ratio | 5.25 |
Current Ratio | 6.46 |
Interest Coverage | — |
Quick Ratio
PRN
Profitability
|
Metric
|
PRN
|
|---|---|
Return on Assets (Normalized) | −46.71% |
Return on Equity (Normalized) | −57.71% |
Return on Invested Capital (Normalized) | −53.16% |
Return on Assets
PRN
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|d>^@Q>m | LOCK|yQ!?% | $179B | |||
| Medtronic PLC
MDT
| LOCK|Z%z^&&f | LOCK|<vSF | $122B | |||
| Stryker Corp
SYK
| LOCK|WZnR%tK | LOCK|W?& | $118B | |||
| Boston Scientific Corp
BSX
| LOCK|$$b$@%P | LOCK|<#!n | $66B | |||
| Edwards Lifesciences Corp
EW
| LOCK|HGxl<wY | LOCK|mL%V | $51B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|$ZYHH! | LOCK|lcw | $32B | |||
| DexCom Inc
DXCM
| LOCK|@<^#pD>^ | LOCK|>rn%k | $29B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|Xv& | LOCK|MB | $26B | |||
| Steris PLC
STE
| LOCK|zv?YZP! | LOCK|bh$<@ | $23B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|!^z>$%^ | LOCK|j$ | $19B |
United States